Zhongzhi Pharmaceutical (03737) announced its 2023 results, with revenue of approximately RMB 2.05 billion (same unit), same...
According to the Zhitong Finance App, Zhongzhi Pharmaceutical (03737) announced its 2023 results, with revenue of approximately RMB 2.05 billion (same unit), up 12.3% year on year; gross profit of RMB 1,218 billion, up 13.6% year on year; profit attributable to the company's equity holders of RMB 163 million, up 53% year on year; profit per share of 0.19 yuan, with a final dividend of HK3 cents per share.
Among them, pharmaceutical revenue increased 25.3% to 1,416 billion yuan, mainly due to the Group's comprehensive promotion and application of the new marketing model, which led to a significant increase in proprietary Chinese medicines.
The division revenue of operating pharmacy chains fell 8.9% to 634 million yuan, mainly due to increased consumer demand for epidemic prevention products due to the liberalization of epidemic control in December 2022, leading to a return to normal demand in the second half of 2023.